Quantum Dot Antigen Density Tuning for Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple sclerosis (MS) are not curative and leave patients immunocompromised, with existing treatments failing to specifically address the autoimmune response against myelin, leading to ongoing inflammation and disease progression.
Innovation Solution
Quantum dots (QDs) conjugated with myelin peptide antigens at tunable densities are used to promote immune tolerance by targeting lymph nodes, where they co-localize with macrophages expressing scavenger receptors, thereby inducing regulatory T cells to control pathogenic T cells attacking myelin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If QDs with higher antigen density are used, then the immune response is more strongly activated, but disease incidence and severity increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the antigen density parameter on QD surfaces. By controlling the number of peptide antigens per QD (e.g., 4:1, 8:1, 16:1 peptide-to-QD ratios), the invention identifies an optimal parameter range that activates immune tolerance without triggering pathogenic responses. This parameter optimization resolves the contradiction between sufficient immune activation and avoidance of disease induction.
Solution Approach 2:
The patent implements local quality by creating heterogeneous QD populations with different antigen densities. Rather than uniform high-density coating, the invention uses a distribution of QDs with varying peptide loads, allowing different regions of the immune system to encounter appropriate antigen densities. This local variation in antigen presentation quality enables selective induction of tolerance while avoiding harmful activation.
2Object-affected harmful factors
If QDs with lower antigen density are used, then disease incidence is reduced, but the immune response activation is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the total antigen load across multiple QD particles rather than concentrating it on fewer high-density QDs. This creates a segmented antigen presentation strategy where numerous low-density QDs collectively deliver the necessary immune signal while avoiding the harmful effects of high local antigen concentration. The segmentation principle resolves the contradiction by distributing immune activation across many weak signals rather than few strong signals.
Solution Approach 2:
The patent employs partial action by using lower-than-maximal antigen densities on each QD. Rather than applying excessive antigen loading to ensure immune activation, the invention uses moderate, distributed antigen presentation that is sufficient for tolerance induction but insufficient to trigger pathogenic responses. This partial action approach optimizes the balance between immune activation and disease prevention.
3Productivity
If uniform high antigen density is applied on QDs, then antigen delivery efficiency is maximized, but tolerance induction is reduced
Solution Approach 1:
The patent resolves this contradiction by changing the density parameter from uniform high values to a distributed range of lower values. By controlling peptide-to-QD ratios during synthesis to achieve heterogeneous loading (e.g., Poisson distribution of peptides per QD), the invention maintains high overall antigen delivery efficiency while ensuring that individual QD-immune cell interactions occur at tolerogenic rather than pathogenic density thresholds.
4Object-affected harmful factors
If existing MS therapies are used, then immune suppression is achieved, but patients remain immunocompromised with ongoing inflammation
Solution Approach 1:
The patent uses QDs as intermediary carriers that mediate antigen delivery to specific immune cell populations. Rather than using broad immunosuppressants that compromise overall immune function, the QD-antigen conjugates act as selective intermediaries that deliver self-antigens to tolerogenic dendritic cell subsets, inducing antigen-specific tolerance while preserving general immune competence. This intermediary approach resolves the contradiction between inflammation control and immune function maintenance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of QDs with lower antigen densities shows delayed disease onset and reduced incidence in MS mouse models, with higher numbers of QDs displaying lower peptide densities being more effective in inducing tolerance, significantly reducing disease severity and incidence.
Implementation Method 1
Quantum dots (QDs) conjugated with myelin peptide antigens at tunable densities
Data Source
Figure 1a~1f
Figure 2a~2f
Figure 3a
AI summary
Provided are compositions and methods for promoting tolerance to auto-immune antigens. In general the compositions include quantum dots (QDs) that are in association with auto-immune peptide antigens. It is shown that QDs can be used to generate immunological tolerance by controlling the density of self-antigen on QDs. Peptide-QDs rapidly concentrate in draining lymph nodes, and co-localize with macrophages expressing scavenger receptors involved in tolerance. Treatment with peptide-QDs reduces disease incidence 10-fold. The degree of tolerance and the underlying expansion of regulatory T cells correlates with the density of myelin molecules presented on QDs such that higher numbers of tolerogenic particles displaying lower levels of self-peptide are more effective for inducing tolerance than fewer particles each displaying higher densities of peptide. The disclosure is therefore relevant to promoting tolerance to antigens that are involved in a variety of autoimmune disorders.